GE HealthCare
GEHC
$71.77
+2.08%
GE HealthCare Technologies is a leading medical technology firm specializing in imaging, ultrasound, patient care solutions, and pharmaceutical diagnostics, operating within the healthcare information services industry. As a market leader in imaging and ultrasound equipment, it holds a distinct competitive position with a diversified revenue stream across four major segments and a global footprint spanning the US, EMEA, China, and other regions. The current investor narrative centers on the company's growth trajectory amid recent cost inflation pressures, which led to a downward revision of 2026 earnings guidance, sparking debate about margin sustainability and the effectiveness of its long sales cycles in offsetting cost headwinds. Additionally, the stock's recent volatility and underperformance relative to the broader market have drawn attention to its turnaround potential and strategic initiatives in digital solutions and AI-driven diagnostics.…
GEHC
GE HealthCare
$71.77
Related headlines
Investment Opinion: Should I buy GEHC Today?
Rating: Hold. GEHC is a quality medical technology leader with a strong competitive position, but near-term margin pressures and growth deceleration warrant caution. The consensus 'buy' rating and average target of $82.50 (17.3% upside) suggest potential, but the recent guidance cut and analyst downgrades temper enthusiasm. The stock is undervalued on forward P/E (12.99x vs. industry 22x), but this discount reflects the market's skepticism about margin recovery.
Sign up to view all
GEHC 12-Month Price Forecast
The AI assessment is neutral with medium confidence. The stock is undervalued on forward earnings, but the margin compression and guidance cut introduce significant uncertainty. The key factor is whether the company can restore margins to historical levels; if it does, the stock could re-rate higher, but if not, the discount may be justified. I would upgrade to bullish if gross margin recovers above 40% and revenue growth accelerates, and downgrade to bearish if margins continue to deteriorate or growth falls below 5%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on GE HealthCare's 12-month outlook, with a consensus price target around $82.50 and implied upside of +14.9% versus the current price.
Average Target
$82.50
0 analysts
Implied Upside
+14.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$70 - $96
Analyst target range
GEHC is covered by 18 analysts, with a consensus recommendation of 'buy' and a mean recommendation score of 1.74 (where 1 is strong buy and 5 is sell). The average target price is $82.50, implying an upside of 17.3% from the current price of $70.31. The distribution includes 10 buy ratings, 6 hold ratings, and 2 sell ratings, reflecting a generally bullish sentiment but with some caution. The target price range spans from a low of $70.00 to a high of $96.00, with the low target suggesting limited downside risk and the high target implying a 36.6% upside. The wide spread of $26 between low and high targets indicates significant uncertainty about the company's future performance, likely due to the cost inflation issues and the ongoing turnaround. Recent institutional ratings show a mix of actions, including UBS upgrading from Sell to Neutral, while Goldman Sachs downgraded from Buy to Neutral, indicating a cautious stance among some major banks. The consensus leans bullish, but the recent downgrades and guidance cut suggest that analysts are closely monitoring the company's ability to manage costs and sustain growth.
Bulls vs Bears: GEHC Investment Factors
GEHC presents a mixed picture: it is fundamentally undervalued on forward earnings and has a strong analyst consensus, but faces significant margin compression and growth deceleration. The bull case rests on the potential for cost mitigation and the stock's historically low valuation, while the bear case highlights the risk of prolonged margin pressure and competitive challenges. Currently, the bearish evidence is slightly stronger given the guidance cut and margin decline, but the valuation discount provides a margin of safety. The key tension is whether the company can offset cost inflation and restore margins to historical levels, which would validate the undervaluation and drive the stock toward analyst targets.
Bullish
- Undervalued on forward earnings: GEHC trades at a forward P/E of 12.99x, a 40.9% discount to the industry average of 22x, and a 27.8% discount to its own trailing P/E of 17.99x. This suggests the market is pricing in significant earnings growth, offering a potential value entry if the company executes its turnaround.
- Strong analyst consensus and upside: With 18 analysts, the consensus is 'buy' (mean score 1.74) and the average target price is $82.50, implying 17.3% upside from the current $70.31. The high target of $96.00 suggests a 36.6% potential gain, reflecting confidence in the company's long-term prospects despite near-term headwinds.
- Solid free cash flow generation: GEHC generated $1.52 billion in trailing twelve-month free cash flow, yielding approximately 4.1% based on the current market cap. This provides a cushion for dividends, debt reduction, and strategic investments, supporting financial flexibility during the cost inflation period.
- Diversified revenue and recurring mix: Revenue is diversified across imaging (45%), advanced visualization (26%), patient care (15%), and pharma diagnostics (14%), with about half recurring from servicing and diagnostics. This reduces dependence on any single product line and provides a stable base, as evidenced by Q1 2026 revenue of $5.13B, up 7.4% YoY.
Bearish
- Margin compression from cost inflation: Gross margin fell to 38.5% in Q1 2026 from 54.3% in Q4 2025, and operating margin dropped to 10.0% from 14.2%. The $250 million cost inflation, which is hard to offset due to long sales cycles, has pressured profitability and led to a 2026 earnings guidance cut.
- Decelerating revenue growth: Q1 2026 revenue growth was 7.4% YoY, but Q4 2025 revenue of $4.67B was down from Q3 2025's $5.14B, indicating a mixed trend. This deceleration raises concerns about the sustainability of growth, especially with macro headwinds in key markets like China.
- Significant underperformance vs. market: GEHC's 1-year price change is +0.5% versus the S&P 500's +21.5%, and its relative strength over 6 months is -24.1%. This underperformance reflects investor skepticism about the company's ability to navigate cost pressures and competitive threats.
- High leverage and debt burden: Debt-to-equity ratio is 0.96, indicating moderate-to-high leverage. Interest expense of $96 million in Q1 2026 consumes a meaningful portion of operating income, and the current ratio of 1.18 suggests limited liquidity buffer, increasing financial risk if earnings deteriorate further.
GEHC Technical Analysis
GEHC's price trend over the past year reflects a significant downtrend, with a 1-year price change of +0.5% compared to the S&P 500's +21.5%, indicating substantial underperformance. The current price of $70.31 sits at approximately 78% of its 52-week range (low $58.75, high $89.77), suggesting the stock is closer to the lower end of its range, which could signal a value opportunity or a falling knife depending on fundamental support. The stock has experienced a maximum drawdown of -32.5% over the period, highlighting the severity of the decline from its highs.
Beta
0.82
0.82x market volatility
Max Drawdown
-32.5%
Largest decline past year
52-Week Range
$59-$90
Price range past year
Annual Return
+0.9%
Cumulative gain past year
| Period | GEHC Return | S&P 500 |
|---|---|---|
| 1m | +11.0% | +2.4% |
| 3m | +13.1% | +4.6% |
| 6m | -11.0% | +11.7% |
| 1y | +0.9% | +21.4% |
| ytd | -13.3% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GEHC Fundamental Analysis
GEHC's revenue trajectory shows moderate growth, with the most recent quarter (Q1 2026) reporting revenue of $5.131 billion, a 7.4% year-over-year increase. However, this growth rate is decelerating compared to prior quarters, as Q4 2025 revenue was $4.674 billion (down from Q3 2025's $5.143 billion), indicating a mixed trend. The imaging segment, which accounts for 45% of revenue, generated $2.299 billion in the latest quarter, while patient care solutions and pharmaceutical diagnostics contributed $704 million and $770 million, respectively, showing diversified but uneven growth across segments. The company's profitability remains solid, with a net income of $389 million in Q1 2026 and a gross margin of 38.5%, though this is down from the 54.3% gross margin in Q4 2025, reflecting cost pressures. Operating margin stood at 10.0% in Q1 2026, down from 14.2% in Q4 2025, indicating margin compression due to the $250 million cost inflation mentioned in recent news. GEHC's balance sheet shows a debt-to-equity ratio of 0.96, indicating moderate leverage, and a current ratio of 1.18, suggesting adequate short-term liquidity. The company generated $1.52 billion in free cash flow over the trailing twelve months, with a free cash flow yield of approximately 4.1% based on the current market cap, providing a cushion for dividends and investments. Return on equity is strong at 20.1%, reflecting efficient use of shareholder capital, though the high debt levels warrant monitoring.
Quarterly Revenue
$5.1B
2026-03
Revenue YoY Growth
+7.4%
YoY Comparison
Gross Margin
38.5%
Latest Quarter
Free Cash Flow
$1.5B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GEHC Overvalued?
Given GEHC's positive net income, the PE ratio is the primary valuation metric. The trailing PE is 17.99x, while the forward PE is 12.99x, indicating that the market expects significant earnings growth, with the forward multiple implying a 27.8% discount to trailing earnings. This gap suggests optimism about future profitability, likely driven by cost mitigation and growth initiatives. Compared to the industry average PE of 22x (based on available data), GEHC's trailing PE of 17.99x represents a 18.2% discount, while the forward PE of 12.99x is a 40.9% discount, suggesting the stock is undervalued relative to peers. This discount may be justified by the company's recent margin pressures and guidance cut, but it also presents a potential value opportunity if the company can execute on its turnaround. Historically, GEHC's PE has ranged from a low of 11.96x in Q4 2022 to a high of 50.01x in Q4 2025, with the current trailing PE of 17.99x near the lower end of this band, indicating that the stock is trading at a historically low valuation, which could signal either a value trap or an attractive entry point depending on future fundamentals.
PE
18.0x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 12x~27x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.3x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are elevated due to margin compression and high leverage. Gross margin fell to 38.5% in Q1 2026 from 54.3% in Q4 2025, and operating margin dropped to 10.0% from 14.2%, reflecting the $250 million cost inflation that is difficult to offset quickly. Debt-to-equity is 0.96, and interest expense of $96 million in Q1 2026 consumes a significant portion of operating income, increasing financial fragility if earnings decline further. The current ratio of 1.18 indicates limited liquidity, and the company's reliance on long sales cycles means cost pressures may persist for several quarters, potentially leading to further guidance cuts.